Key Insights

Highlights

Success Rate

64% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

29.4%

5 terminated out of 17 trials

Success Rate

64.3%

-22.2% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

56%

5 of 9 completed with results

Key Signals

5 with results64% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (1)
P 1 (4)
P 2 (10)

Trial Status

Completed9
Terminated5
Unknown2
Recruiting1

Trial Success Rate

64.3%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT00830557RecruitingPrimary

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

NCT00427349Phase 2Completed

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NCT00227617Phase 2Terminated

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

NCT00730483Not ApplicableTerminated

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

NCT01374451Phase 2TerminatedPrimary

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

NCT00049023Phase 1Completed

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00416767Phase 2Completed

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

NCT00002947Phase 1Terminated

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT02038738Phase 1Unknown

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

NCT00454376Unknown

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

NCT00602082Phase 2Completed

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

NCT00027638Phase 2Completed

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

NCT00006368Phase 1Completed

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00017199Phase 2Completed

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

NCT00434109Phase 2Completed

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

NCT00466856Phase 2Terminated

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

NCT00019786Phase 2Completed

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases

Showing all 17 trials

Research Network

Activity Timeline